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Abstract
Background: To investigate the expression of cyclin-dependent kinase 8 (CDK8) and b-catenin in colon cancer and
evaluate the role of CDK8 in the proliferation, apoptosis and cell cycle progression of colon cancer cells, especially
in HCT116 cell line.
Methods: Colon cancer cell line HCT116 was transfected with small interfering RNA (siRNA) targeting on CDK8.
After CDK8-siRNA transfection, mRNA and protein expression levels of CDK8 and b-catenin were determined by
reverse transcriptase-polymerase chain reaction (RT-PCR) and Western blot assay in HCT116 cells. Cell proliferation
was measured by 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide Methylthiazolyl tetrazolium (MTT)
assay, and cell cycle distribution and apoptosis were analyzed by flow cytometry analysis (FACS). CDK8 and b-
catenin protein levels were also examined by real-time PCR and immunohistochemistry (IHC) in colon cancer
tissues and adjacent normal tissues.
Results: After CDK8 specific siRNA transfection, mRNA and protein expression levels of CDK8 and b-catenin in
HCT116 cells were noticeably decreased (P < 0.05). CDK8 specific siRNA transfection inhibited HCT116 cells’
proliferation and facilitated their apoptosis significantly (P < 0.05). In addition, the proportion of HCT116 cells in the
G0/G1 phase was remarkably increased after CDK8-siRNA transfection (P < 0.05). The expression levels of CDK8 and
b-catenin in adjacent normal tissues were lower than in tumor tissues (P < 0.05). Moreover, the expression of CDK8
was correlated with the expression of b-catenin in both tumor and adjacent normal tissues (P < 0.05).
Conclusions: CDK8 and b-catenin were expressed in colon cancer at a high frequency. CDK8 specific siRNA
transfection down-regulated the expression of CDK8 in colon cancer cells, which was also associated with a
decrease in the expression of b-catenin Moreover, CDK8 specific siRNA inhibited the proliferation of colon cancer
cells, promoted their apoptosis and arrested these cells in the G0/G1 phase. Interference of CDK8 might be an
effective strategy through b-catenin regulation of colon cancer.
Background
Colon cancer is a result of an evolving process charac-
terized by alterations of multiple genes and dysregulated
cell signal transduction pathways. It has been well
known that mutations of key genes in the Wnt/b-cate-
nin signaling pathway play an important role in the
occurrence and development of colon cancer [1,2].
Under physiological conditions, Wnt contributes to the
stabilization of b-catenin. Once stabilized, b-catenin
accumulates and migrates to the nucleus. On the other
hand, when the level of b-catenin within the cytoplasm
surpasses the threshold, the molecule migrates to the
nucleus, binds to the transcription factor, and exposes
the promoters of downstream genes, such as c-myc,
cyclinD1, survivin, gastrin, vascular endothelial growth
factor (VEGF), and associated exchange factors (Asef).
Finally, these activated genes contribute to abnormal
cellular proliferation [3,4].
Cyclin-dependent kinase (CDK) 8 is located in chro-
mosome 13q12.13 and is a member of the CDK family
[5,6]. CDK is classified as a serine-threonine protein
kinase, and ten of its members have been identified in
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homology to a certain extent. CDK has a catalytic subu-
nit that is activated in the presence of a regulatory subu-
n i tp r o v i d e db yc y c l i n[ 7 ] ,w hich leads to the formation
of a mediator complex together with MDE12 and
MED13. The mediator complex can bind to RNA poly-
merase II, which participates in eukaryotic gene tran-
scription such as the transcription of the b-catenin
signaling pathway. Taken together, CDK8 plays an
important regulatory role in cell cycle control and cell
growth at the transcription level and it is proposed to
be a proto-oncogene in human colon cancer [8-10]. As
far as we know, studies on the role of CDK8 in the pro-
liferation, apoptosis and cell cycle progression of colon
cancer cells are still insufficient [11]. RNA interference
(RNAi) has emerged as a powerful tool to induce lose-
of-function phenotypes by post-transcriptional silencing
of gene expression [12,13]. In the present study, CDK8
specific interference was designed and transfected into a
colon cancer cell line HCT116. The effect of small inter-
fering RNA (siRNA) silencing of CDK8 on the growth of
colon cancer cells was investigated. In addition, we veri-
fied the mRNA and protein expression levels of CDK8
and b-catenin in colon cancer tissues.
Methods
Major reagents
Rabbit anti-human CDK8 antibody, rabbit anti-human
b-catenin antibody, and rat anti-human b-actin antibody
were purchased from Chemicon (USA). Lipofectin2000
was provided by Invitrogen (USA). RT-PCR kits were
purchased from Fermentas (USA). Annexin V apoptosis
kit (Keygentec, China) and siRNA-CDK8 (Genepharma,
China) were used in the present study.
Cell culture
The human colon cancer cell line, HCT116 cell line was
purchased from Shanghai Cell Biology Institutes, Chi-
nese Academy of Sciences (Shanghai, China). HCT116
cell line was seeded in 6-well plate at a density of 1.5 ×
10
5/well and maintained in RPMI1640 (Invitrogen,
USA) supplemented with 10% fetal bovine serum (FBS).
All cells were cultured at 37°C in a humidified atmo-
sphere containing 5% CO2.
Transfection with CDK8-siRNA
CDK8 siRNA sequence 5’-AUAUAAUAGUGACUU-
CACCAUUCCCTT-3’ (S) 5’-GGGAAUGGUGAAGU-
VAVUAUUAUAUTT-3’ (AS) and scrambled siRNA
sequence 5’-UUCUCCGAACGUGUCACGUTT-3’ (S)
5’-ACGUGACACGUUCGGAGAATT-3’ (AS) were
designed and synthesized by Genepharma (Shanghai,
China). HCT116 cells (1.5 × 10
5) were divided into
three groups: (a) siRNA-CDK8 group, (b) scrambled
siRNA group, and (c) non-siRNA control group. One
hour before transfection, the medium was replaced with
1.5 ml of serum free Opti-MEM. Then, the following
reagents were mixed as follows: (a) 4 μl of Lipofec-
tin2000 were added to 250 μlo fO p t i - M E M ,a n dt h e
mixture was kept at room temperature for 5 min; (b) 4
μl of siRNA stock solution were added to 250 μlo f
Opti-MEM (siRNA dilution); and (c) the above two mix-
tures were then mixed and kept at room temperature
for 20 min (siRNA-Lipofectin2000 mixture). After shak-
ing, this siRNA-Lipofectin2000 mixture was then added
to a 6-well plate (1.5 ml of Opti-MEM in each well). Six
hours later, the medium was replaced with complete
medium. Our previous study confirmed that we
obtained the maximal transfection efficacy when the
ratio of Lipofectin2000 to siRNA was 4 μl:4 μl.
MTT assay
Six hours after transfection, HCT116 cells were digested,
re-suspended and seeded in a 96-well culture plate.
After 24, 48 and 72 h of incubation, cells were stained
with 20 μl 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenylte-
trazolium bromide Methylthiazolyl tetrazolium (MTT)
solution (5 mg/ml) at 37°C for 4 h and subsequently
made soluble in 150 μl of DMSO. Absorbance (A) was
measured at 490 nm with an automated plate reader.
Each sample was triplicated and the experiment was
repeated three times. Cell growth curves were calculated
as mean values of each group.
Flow cytometric analysis
Cells were trypsinized and centrifuged at 1500 rpm/min
for 5 min at 48 h after transfection. Cells were harvested
and washed with Phosphate Buffered Saline (PBS) twice.
Reagents for apoptosis detection were added, and then
cells were incubated in dark for 30 min and subjected to
flow cytometry analysis (FACS). Additionally, cells were
collected, washed with PBS, fixed with 75% ethanol at-
20°C overnight, and centrifuged at 1500 rpm/min for 5
min. Then, ethanol was removed and cells were washed
with PBS twice. Propidium iodide (PI) and 500 μlo f
RNAse were added, and then cells were incubated in
dark at 4°C for 60 min. Lastly, cells were subjected to
cell cycle analysis by FACS.
Gene expression analysis (RT-PCR and real-time PCR)
The mRNA expression of CDK8 and b-catenin in
HCT116 cells after CDK8-siRNA transfection were
quantified by RT-PCR. Total RNA was extracted from
cells with Trizol and subjected to reverse transcription
into cDNA. CDK8 and b-catenin were amplified from
the cDNA by RT-PCR. The PCR conditions consisted of
5 min at 94°C one cycle, 30 s at 94°C, 40 s at 55°C, 45 s
at 72°C, and 7 min at 72°C 40 cycles. The primer
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TAGC-3’ (forward) and 5’-CTGATGTAGGAAGTGG
GTCT-3’ (reverse) for CDK8; 5’-TGCCAAGTGGGTGG
TATAGAG-3’ (forward) and 5’-TGGGATGGTGGGTG
TAAGAG-3’ (reverse) for b-catenin; 5’CTGGGACGA
CATGGAGAAAA3’ (forward) and 5’AAGGAAGGCTG
GAAGAGTGC3’ (reverse) for b-actin.
The mRNA expression of CDK8 and b-catenin in
colon cancer samples (n = 12) were quantified by real-
time PCR. Informed consent was obtained from all the
patients, and research protocols were approved by Inde-
pendent Ethics Committee (IEC) of our hospital. A total
of 200 mg of tumor or adjacent normal tissues (at least
2 cm distant from the tumor site) were homogenized in
liquid nitrogen. Total RNA was extracted and reverse
transcribed into cDNA, which was then used for ampli-
fication of CDK8 and b-catenin. The real time PCR con-
ditions consisted of 1 cycle at 94°C for 10 min followed
by 40 cycles at 94°C for 30 s, at 55°C for 30 s, and at
72°C for 30 s. GAPDH was employed as an internal
standard. The primer sequences were as follows: 5’-
GAGCGGGTCGAGGACCTGTTTGAAT-3’ (forward)
and 5’-ACATGCCGACATAGAGATCCCAGTTCCT
TC-3’ (reverse) for CDK8; 5’-TGCCAAGTGGGTGG
TATAGAG-3’ (forward) and 5’-TGGGATGGTGGGTG
TAAGAG-3’ (reverse) for b-catenin; 5’AGGGGCCATC-
CACAGTCTTC3’ (forward) and 5’ AGAAGGCTG
GGGCTCATTTG 3 (reverse) for GAPDH. The 2
-ΔΔCT
method was applied to analyze the relative changes in
gene expression.
Western blot analysis
As described previously [14], following 72 h of transfec-
tion, total protein was extracted from HCT116 cells and
subjected to SDS-PAGE. Protein concentrations were
transferred onto PVDF membrane, then membranes
were blocked and incubated with rabbit anti-human
CDK8 (1:1000) or b-catenin antibody (1:1000) at 4°C
overnight. After 3 washes with TBS-T solution for 10
min, the membranes underwent hybridization with a
goat anti-rabbit IgG secondary antibody (1:1000) at 37°C
f o r1h .A f t e rf u r t h e rw a s h i n g ,C D K 8a n db-catenin
levels were visualized using an ECL chemiluminescence
kit.
Immunohistochemistry
The protein expression of CDK8 and b-catenin in 47
tumor tissues and adjacent normal tissues were detected
by IHC. Samples were fixed in 10% neutral formalde-
hyde, embedded in paraffin, and sliced. Briefly, the par-
affin-embedded tissues were serially cut into 4 μm
sections, dewaxed, and rehydrated. Sections were then
blocked with peroxide and non-immune animal serum
and incubated sequentially with rat anti-human CDK8
and b-catenin (1:1000), and biotin-labeled goat anti-rab-
bit IgG (1:1000). Finally, the sections were stained with
DBA, counterstained with hematoxylin, dehydrated,
cleared in xylene, and fixed.
Histological assessment was performed as described
previously [15]. Immunostaining was independently
examined by two clinical pathologists who were unaware
of the patient outcome. Five high-power fields (400 ×
magnification) were randomly counted for each section.
The brown staining on the cytoplasm was read as posi-
tive reactivity for CDK8 and b-catenin. The presence of
brown colored granules on the cytoplasm was taken as a
positive signal, and was divided by color intensity into
not colored, light yellow, brown, tan and is recorded as
0, 1, 2, 3, respectively. We also choose five high-power
fields from each slice and score them. Positive cell rate
of < 25% was a score of 1, positive cell rate of 25~50%
was a score of 2, positive cell rate of 51~75% was a
s c o r eo f3 ,p o s i t i v ec e l lr a t eo f>7 5 %w a sas c o r eo f4 .
The final score was determined by multiplying positive
cell rate and score values: 0 was equal to negative ( - ),
1~4 was equal to weakly positive (+), 5~8 was equal to
moderate positive(+ +), 9~12 was equal to strongly posi-
tive (+ + +).
Statistical analysis
All data were presented as means ± standard deviation
(SD). A Student’s t-test was used for comparisons
between groups, and F test was applied for correlation
analyses. Statistical analysis was performed with SPSS
13.0 statistic software package. P values < 0.05 were
considered to be statistically significant.
Results
Effect of CDK8-siRNA transfection on CDK8 and b-catenin
expression in HCT116 cells
Six hours after CDK8-siRNA transfection, the transfec-
tion efficiency was detected by FACS. Our previous
study confirmed that the maximal transfection efficacy
could be obtained when the ratio of Lipofectin 2000 to
siRNA was 4 μL: 4 μL. (Figure 1)
Forty-eight hours later of CDK8-siRNA transfection,
RT-PCR was performed to detect CDK8 and b-catenin
mRNA expression. The results showed that mRNA
expression of CDK8 and b-catenin was markedly lower
in the CDK-siRNA group compared with the other two
groups (P < 0.01) (Figure 2). However, there was no sig-
nificant difference in mRNA expression between the
scrambled siRNA group and non-siRNA group.
Following a 72 h CDK8-siRNA transfection of
HCT116 cells, protein expression of CDK8 and b-cate-
nin was determined by western blot assay. As shown in
figure 3, CDK8 and b-catenin expression was remark-
ably reduced in the CDK-siRNA group compared to the
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Page 3 of 9Figure 1 Transfection efficiency determined by flow cytometry. The transfection efficiency was 97.2% 6 h after transfecting with CDK8-siRNA
of HCT116. The ratio of Lipofectin 2000 to siRNA was 4 μL: 4 μL, and the concentration of CDK8-siRNA is 80 pmol/L.
Figure 2 CDK8 and b-catenin mRNA expression of CDK-siRNA transfected HCT116 cells detected by RT-PCR.4 8hl a t e ro fC D K 8 - s i R N A
transfection, RT-PCR was performed to detect CDK8 and b-catenin mRNA expression. A: CDK8-siRNA group; B: scrambled siRNA group; C: non-
siRNA group; D, E and F represented corresponding internal reference, and M: marker. Results are given as average value of the gray in three
target genes and interal controls from three independent experiments.
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Page 4 of 9other two groups (P < 0.01). Similarly, there was no sig-
nificant difference between the scrambled siRNA group
and non-siRNA group.
Effect of CDK8-siRNA transfection on the growth of
HCT116 cells
The cell proliferation of HCT116 cells following 24, 48 and
72 h of transfection was detected by MTT assay. Results
showed that the number of viable cells in the CDK8-
siRNA group was significantly lower compared to that of
the scrambled siRNA and non-siRNA groups 48 and 72 h
after CDK8-siRNA transfection (P < 0.05) (Figure 4).
Effect of CDK8-siRNA transfection on the apoptosis and
cell cycle of HCT116 cells
We performed experiments to evaluate the apoptosis
and cell cycle of HCT116 cells by CDK8-siRNA. As
shown in figure 5, following 48 h transfection, it was
indicated that the rate of apoptosis in the CDK8-siRNA
group (23.50 ± 1.20%) was significantly higher than that
of the scrambled siRNA (4.87 ± 1.48%) and non-siRNA
groups (4.77 ± 1.42%) (P < 0.01) (Figure 5A). On the
other hand, the cell cycle analysis showed that G0/G1
phase of CDK8-siRNA transfected group in a ratio of
65.77 ± 1.17%, was significantly higher than that of
Figure 3 Representative Western blots of CDK8 and b-catenin expression level in CDK-siRNA transfected HCT116 cells.7 2hl a t e ro f
CDK8-siRNA transfection of HCT116 cells, protein expression of CDK8 (A) and b-catenin (B) was determined by western blot assay. a: non-siRNA
group; b: scrambled siRNA group; c: CDK-siRNA group. Results are given as average value of the gray in three target genes and interal controls
from three independent experiments.
Figure 4 Cell proliferation activity after transfection of CDK8-siRNA assessed by MTT assay. Curves of cell growth after transfection for 24,
48 and 72 h by MTT assay. Results are given as means ± SD from three independent experiments. P < 0.05.
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Page 5 of 9scrambled siRNA (50.20 ± 2.43%) and non-siRNA group
(54.33 ± 2.55%) (P < 0.01) (Figure 5B).
CDK8 and b-catenin expression in fresh colon tumor and
adjacent normal tissues
To further confirm the expression of CDK8 and b-cate-
nin in colon cancer, we detected the expression of
CDK8 and b-catenin in fresh colon cancer tissues and
adjacent normal tissues of the same patient. Real-time
PCR was adopted to detect the mRNA levels. Results
showed that mRNA expression levels of CDK8 and b-
catenin in tumor tissues was significantly higher than in
adjacent normal tissues (P < 0.05) (Figure 6). In addi-
tion, the expression of CDK8 was correlated with the
expression of b-catenin in both tumor tissues (r = 0.744,
P < 0.01) and adjacent normal tissues (r = 0.650, P <
0.05).
Shown by IHC, the positive cells were expressed as
brown particles distributed in the cytoplasm of tumor
cells (Figure 7). Of the 47 colon tumors, the positive
rate of CDK8 and b-catenin was 76.6% (36/47) and
95.7% (45/47). However, in adjacent normal tissues, the
positive rate was 21.3% (10/47) and 88.9% (40/47),
respectively. The difference between them was
statistically significant (P < 0.05). As predicted, the
expression of CDK8 was also correlated with the expres-
sion of b-catenin in both tumor tissues (r = 0.485, P <
0.05) and adjacent normal tissues (r = 0.346, P < 0.05).
Discussion
Aberrant activation of the Wnt/b-catenin pathway has
been shown to be associated with numerous human
cancers [1,2,16]. Previous studies revealed that an
abnormality in b-catenin signaling pathway may be
responsible for almost all types of colon cancers [4,17].
It has been reported that CDK8 plays a central role in
the regulation of b-catenin activation [3,18]. Based on
such a background, further exploring of the role of
CDK8 and b-catenin in the oncogenesis and progression
of colon cancer as well as their correlation, not only
provides a broad understanding of the etiology of colon
cancer, but also may provide an intervention stategy
with CDK8 and b-catenin as a target.
Ron Firestein et al [8] found that CDK8 was necessary
for the b-catenin-mediated activation of proto-onco-
genes. They noted that, in the absence of CDK8, the
activity of b-catenin-mediated transcription was signifi-
cantly decreased, whereas an overexpression of CDK8
Figure 5 Effect of CDK8-siRNA transfection on the apoptosis and cell cycle of HCT116 cells. 48 h after transfection, cell apoptosis (A) and
cell cycle (B) were determined by flow cytometry. Quadrants D2-D4 represent necrotic/late apoptotic cells, viable cells, and early apoptotic cells,
respectively. Results are given as means ± SD from three independent experiments.
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ally, Morris and colleagues screened E2F1-dependent
apoptotic genes and found that E2F1 could inhibit Wnt/
b-catenin activity and CDK8 was the most potential
i n h i b i t o ro fE 2 F 1[ 9 , 1 9 ] .F u r t h e r m o r e ,C D K 8m a ya l s o
be involved in other signaling pathways. It is reported
that CDK8 is a positive co-stimulatory regulator of the
expression of p53 gene [20] and p53’s downstream gene
p21 since the binding of CDK8 to the p53 gene can
increase its transcription activity. Furthermore, CDK8
could regulate the Notch signaling pathway [21] and
exerted positive regulatory effects on the tumorigenicity
related mRNA prolongation [22]. Therefore, CDK8 may
be considered to be a proto-oncogene based on the
above observations.
To investigate the effects of the activity of b-catenin
on colon cancer through CDK8, CDK8 interference was
constructed and transfected in colon cancer cells CT116
by the application of siRNA in our study. The alteration
of the expression of b-catenin, proliferation, cell apopto-
sis and cell cycle distribution in HCT116 cells were
determined. After silencing CDK8 by siRNA, our results
showed that b-catenin expression was markedly lower at
the mRNA and protein level, and it is considered that
there was a significant association between CDK8 and
b-catenin expression. Such results support the claim of
Ron Firestein et al [ 8 ]t h a to n l yC D K 8p l a yac e n t r a l
role of post-translational modulator of b-catenin in
colon cancer. Additionally, it was showed that cell pro-
liferation was reduced after CDK8 blocking using MTT
assay. Flow cytometry analysis revealed that the rate of
cell apoptosis in the CDK8-siRNA group was markedly
higher compared to the control groups, and the majority
of cells was in the G0/G1 phase in the CDK8-siRNA
group. We suggest that CDK8-siRNA transfection may
decrease cell proliferation and facilitate apoptosis of
colon cancer cells. Furthermore, the cell cycle arrest
after CDK8-siRNA transfection may be related to the
reduced transcription activity of b-catenin, since b-cate-
nin can regulate the expression of certain cell cycle-
related genes, including survivin and c-myc. However,
the exact effect and mechanism on these downstream
genes of b-catenin followed with marked reduction of
CDK8 needs to be elucidated in future studies. Accord-
ing to our results, it was speculated that the possibility
of the regulation of colon cancer through control of
CDK8 is theoretically applicable.
To confirm the expression and relationship of CDK8
and b-catenin based on colon cancer tissues, real-time
PCR and IHC were performed in our study. As pre-
dicted, both CDK8 and b-catenin expression level were
markedly higher in tumor compared to adjacent normal
tissues. Furthermore, the expression of b-catenin
showed positively related toC D K 8e x p r e s s i o n .M e a n -
while, it is reported that the expression of b-catenin was
still positive or high in some colon cancer cell lines that
have negative expression of CDK8. It is suggested that
there might be other factors for regulating the activity
of b-catenin such as pancreatic adenocarcinoma up-
regulated factor (PAUF) [23] and Delta-like4 (DLL4)
[24] expect CDK8. Neverthless, our observations sug-
gested that CDK8-siRNA can effectively inhibit the tran-
scription activity of the b-catenin signaling pathway in
colon cancer cells HCT116, thereby resulting in the
Figure 6 CDK8 and b-catenin mRNA expression in colon tumor and adjacent normal tissues detected by real-time PCR. Fresh tumor
and corresponding adjacent tissues from 12 patients were resected under sterile conditions and then snapfrozen in liquid nitrogen immediately.
200 mg tissue was taken out from liquid nitrogen and plused 1 ml Trizol when RNA was extaracted. Real-time PCR is performed for the
expression levels of CDK8 (A) and b-catenin (B). Results are given as means ± SD from three independent experiments. P < 0.05.
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tosis. Further studies would be of interest to determine
whether silencing CDK8 and other factors together
could amplificate the silencing effect of the b-catenin.
Based on the high specificity of CDK8 to b-catenin,
CDK8 may be used as an alternative target in the regu-
lation of colon cancer. Given the number of CDK inhi-
bitors are being applied in clinical practice [25,26],
Figure 7 CDK8 and b-catenin protein expression in colon tumor and adjacent normal tissues detected by IHC. The expression of CDK8
(left) and b-catenin (right) was stained brown and present in tumor tissue and adjacent normal tissues. Representative sites with negative (a, 400
X ), moderate positive (c, 400 × ), strongly positive (e, 400 ×) expression of CDK8 and corresponding weakly positive (b, 400 ×), moderate
positive (d, 400 ×), strongly positive (f, 400 ×) expression of b-catenin.
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power of specific CDK8 inhibitors candidate on the
downregulation of b-catenin expression, and subse-
quently on the inhibition of proto-oncogenes. Our
observations demonstrated that the activity of CDK8 is
e s s e n t i a lt ob ea b l et or e g u l a t eb-catenin-dependent
transcription and transformation in colon cancer cells.
Accordingly, it is indicated that the intervene stategy
targeting CDK8 in colon cancer may be of clinical value.
Conclusions
In this study, we demonstrated that CDK8 specific
siRNA transfection down-regulated the expression of
CDK8, which is expressed in a high fraction in colon
cancer. We also found out that CDK8 specific siRNA
inhibited the proliferation of colon cancer cells, pro-
moted their apoptosis and arrested these cells in the
G0/G1 phase. In addition, CDK8 inhibition may be
associated with the down-regulation of b-catenin. Our
results showed that CDK8 and b-catenin could be pro-
mising target in the regulation of colon cancer by the
control of b-catenin through CDK8.
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